Vosoritide (original) (raw)
Vosoritid ist ein Peptid aus 39 Aminosäuren, das als Arzneistoff zur Behandlung des angeborenen Kleinwuchses (Achondroplasie) verwendet wird. Unter dem Namen Voxzogo wurde es im August 2021 in der EU, im November 2021 in den USA zugelassen. Vosoritid ist eine modifizierte Version des natürlich vorkommenden (CNP). Es wird subkutan verabreicht.
| Property | Value |
|---|---|
| dbo:abstract | Vosoritid ist ein Peptid aus 39 Aminosäuren, das als Arzneistoff zur Behandlung des angeborenen Kleinwuchses (Achondroplasie) verwendet wird. Unter dem Namen Voxzogo wurde es im August 2021 in der EU, im November 2021 in den USA zugelassen. Vosoritid ist eine modifizierte Version des natürlich vorkommenden (CNP). Es wird subkutan verabreicht. (de) Vosoritida (denominación común internacional -DCI-,INN en inglés, también conocida como BMN-111) es un medicamento experimental para el tratamiento de la causa más común del enanismo: la acondroplasia. ha desarrollado este fármaco. Siendo el único tratamiento causal disponible para esta condición, en los Estados Unidos y en Europa tiene estatus de medicamento huérfano. A septiembre de 2015 estaba en fase II de ensayos clínicos. (es) Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia. The most common side effects include injection site reactions (such as swelling, redness, itching, or pain), vomiting, and decreased blood pressure. Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth. The average height of an adult with achondroplasia is approximately four feet. People with achondroplasia have a genetic mutation that causes a certain growth regulation gene called fibroblast growth factor receptor 3 to be overly active, which prevents normal bone growth. Vosoritide works by binding to a specific receptor called natriuretic peptide receptor-B that reduces the growth regulation gene's activity and stimulates bone growth. Vosoritide was approved for medical use in the European Union in August 2021, and in the United States in November 2021. (en) |
| dbo:alternativeName | Voxzogo (en) |
| dbo:casNumber | 1480724-61-5 |
| dbo:drugbank | DB11928 |
| dbo:fdaUniiCode | 7SE5582Q2P |
| dbo:kegg | D11190 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Vosoritid.svg?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/vosoritide%7Cpublisher |
| dbo:wikiPageID | 47764552 (xsd:integer) |
| dbo:wikiPageLength | 19003 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1113175335 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Proline dbr:C-terminal dbr:C-type_natriuretic_peptide dbr:BioMarin_Pharmaceutical dbr:Hydrocephalus dbr:Peptide dbr:Indication_(medicine) dbr:Oral_administration dbr:Orphan_drug dbr:Glutamic_acid dbr:Glutamine dbr:Glycine dbr:Leucine dbr:Lysine dbr:Body_proportions dbr:Chondrocyte dbr:Sleep_apnea dbr:Subcutaneous_injection dbr:Clinical_trial dbr:P-value dbr:Tyrosine dbr:Achondroplasia dbr:Alanine dbc:Orphan_drugs dbr:Cysteine dbr:Food_and_Drug_Administration dbr:Basic_fibroblast_growth_factor dbr:Cell_proliferation dbr:Receptor_(biochemistry) dbr:Histidine dbr:Isoleucine dbr:Arginine dbr:Asparagine dbr:Aspartic_acid dbc:Dwarfism dbr:Phenylalanine dbr:Fibroblast_growth_factor_receptor_3 dbr:Methionine dbr:Cartilage dbr:Serine dbr:Disulfide_bridge dbr:Peptide_sequence dbr:Epiphyses dbr:Analog_(chemistry) dbr:Acidic_fibroblast_growth_factor dbr:File:Vosoritide_mechanism.png |
| dbp:atcPrefix | M05 (en) |
| dbp:atcSuffix | BX07 (en) |
| dbp:c | 176 (xsd:integer) |
| dbp:casNumber | 1480724 (xsd:integer) |
| dbp:chemspiderid | 44210446 (xsd:integer) |
| dbp:dailymedid | Vosoritide (en) |
| dbp:drugbank | DB11928 (en) |
| dbp:h | 290 (xsd:integer) |
| dbp:kegg | D11190 (en) |
| dbp:legalAu | S4 (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:n | 56 (xsd:integer) |
| dbp:o | 51 (xsd:integer) |
| dbp:pregnancyAu | B2 (en) |
| dbp:routesOfAdministration | dbr:Subcutaneous_injection |
| dbp:s | 3 (xsd:integer) |
| dbp:smiles | CC[C@H][C@H]1CNCCN[C@H]CO (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | IGYWDDBBJPSOTG-WBAGYEQSSA-N (en) |
| dbp:synonyms | BMN-111 (en) |
| dbp:tradename | Voxzogo (en) |
| dbp:unii | 7 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:As_of dbt:Cite_web dbt:Convert dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:ClinicalTrialsGov |
| dcterms:subject | dbc:Orphan_drugs dbc:Dwarfism |
| gold:hypernym | dbr:Drug |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Vosoritid ist ein Peptid aus 39 Aminosäuren, das als Arzneistoff zur Behandlung des angeborenen Kleinwuchses (Achondroplasie) verwendet wird. Unter dem Namen Voxzogo wurde es im August 2021 in der EU, im November 2021 in den USA zugelassen. Vosoritid ist eine modifizierte Version des natürlich vorkommenden (CNP). Es wird subkutan verabreicht. (de) Vosoritida (denominación común internacional -DCI-,INN en inglés, también conocida como BMN-111) es un medicamento experimental para el tratamiento de la causa más común del enanismo: la acondroplasia. ha desarrollado este fármaco. Siendo el único tratamiento causal disponible para esta condición, en los Estados Unidos y en Europa tiene estatus de medicamento huérfano. A septiembre de 2015 estaba en fase II de ensayos clínicos. (es) Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia. The most common side effects include injection site reactions (such as swelling, redness, itching, or pain), vomiting, and decreased blood pressure. Vosoritide was approved for medical use in the European Union in August 2021, and in the United States in November 2021. (en) |
| rdfs:label | Vosoritid (de) Vosoritida (es) Vosoritide (en) |
| owl:sameAs | yago-res:Vosoritide wikidata:Vosoritide dbpedia-de:Vosoritide dbpedia-es:Vosoritide https://global.dbpedia.org/id/zfDf |
| prov:wasDerivedFrom | wikipedia-en:Vosoritide?oldid=1113175335&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Vosoritid.svg wiki-commons:Special:FilePath/Vosoritide_mechanism.png |
| foaf:isPrimaryTopicOf | wikipedia-en:Vosoritide |
| is dbo:wikiPageRedirects of | dbr:Voxzogo |
| is dbo:wikiPageWikiLink of | dbr:BioMarin_Pharmaceutical dbr:Achondroplasia dbr:ATC_code_M05 dbr:Voxzogo |
| is foaf:primaryTopic of | wikipedia-en:Vosoritide |
